Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21676411 | 0.85 | ALDH1A1 (0.39) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL20017286 | 0.83 | EPHX1 (0.52) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL18793674 | 0.80 | POLB (0.45) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL1233423 | 0.80 | TSHR (0.39) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL24567754 | 0.80 | POLB (0.45) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL22338262 | 0.80 | EPHX1 (0.42) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL19172100 | 0.80 | EPHX1 (0.62) | POLBALDH1A1EPHX1SMN1; SMN2TSHR | |
| SCHEMBL6488391 | 0.78 | POLB (0.43) | POLBTRPA1ALDH1A1MEN1KMT2A | |
| SCHEMBL2625566 | 0.78 | EPHX1 (0.48) | POLBALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6488388 | 0.78 | POLB (0.43) | POLBTRPA1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| EP-4265608-A1 | BENZOHETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230192634-A1 | Antiviral Compounds for Use in the Treatment of Coronavirus Infection | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192634-A1 | Antiviral Compounds for Use in the Treatment of Coronavirus Infection | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-11678968-B2 | Urological device including a valve retained in a urinary catheter | COLOPLAST A/S (DK) | 2023-06-20 | — | — | US | disclosed |
| US-11678968-B2 | Urological device including a valve retained in a urinary catheter | COLOPLAST A/S (DK) | 2023-06-20 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2023-05-16 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | POLB 2106/4885TRPA1 4837/4885ALDH1A1 3864/4885 |
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | POLB 1247/4885TRPA1 2839/4885ALDH1A1 4074/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | POLB 391/4885TRPA1 3751/4885ALDH1A1 3464/4885 |
| US-20230192634-A1 | Antiviral Compounds for Use in the Treatment of Coronavirus Infection | SARS1, MAVS, ZC3HAV1 | POLB 400/4885TRPA1 4660/4885ALDH1A1 4490/4885 |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | POLB 4812/4885TRPA1 2863/4885ALDH1A1 3655/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | POLB 273/4885TRPA1 4588/4885ALDH1A1 424/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | POLB 3486/4885TRPA1 3374/4885ALDH1A1 4424/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | POLB 1097/4885TRPA1 4372/4885ALDH1A1 4520/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | POLB 3689/4885TRPA1 209/4885ALDH1A1 1999/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | POLB 2106/4885TRPA1 4837/4885ALDH1A1 3864/4885 |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | NOTCH1, CHUK, CBFB | POLB 1085/4885TRPA1 3819/4885ALDH1A1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.